Amarex Ranked as a Top Bioscience Employer
Germantown, MD, USA (August 31, 2017) – Amarex Clinical Research, LLC is pleased to announce that it has been ranked No. 20 by the Washington Business Journal in its Top 25 Bioscience Employers.
The rankings were published August 2017. Attached is the complete list of the Top 25 Bioscience Employers. “Washington Business Journal provides important market intelligence with its List research.” said James MacGregor, Publisher and Market President of the Washington Business Journal. “Amarex, along with all of the companies on the List, deserve special recognition because they fuel our regional economy.”
“Amarex is pleased to once again be listed amongst the top bioscience employers in the Greater Washington, DC area. This marks our fourth consecutive year of being recognized by the Washington Business Journal. It is a testament to not only Amarex’s continued growth, but to the overall health of our local ecosystem.” said Dr. Kazem Kazempour, CEO and President of Amarex Clinical Research.
Washington Business Journal Bioscience Employers
About Amarex Clinical Research
Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs, FDA Applications and Submissions, Applications and Submissions to international Health Authorities, GxP Compliance Audits, Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management and General Consulting. Amarex has taken clients’ products through the entire approval process from writing the initial product approval strategy to the marketing approval application with a growing list of approved products. Amarex is committed to cost effective, high quality clinical product development.
Book a meeting or send us a message to talk to one of our experts.